Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019–Related Hospital Outcomes in Patients with Type 2 Diabetes
Authors' conclusion
In this population, limited to type 2 DM and controlled for multiple variables that have not been consistently studied (such as a measure of general health, glycated hemoglobin, and insurance status), insulin prescription was associated with increased ICU admission. Metformin and DPP4i prescriptions did not have an association with the outcomes.
Study context
- Population
- Patients with T2D hospitalized with COVID-19, single hospital systemfinal analysis
- Participants
- 529 patients
- Exposure
- Metformin, DPP-4i and insulin prescription vs no prescription
- Outcome
- ICU admission, need for assisted ventilation, development of renal insufficiency and mortality
Methodological detailssingle hospital system, univariate and multivariate analyses
- Single hospital system
- Univariate and multivariate analyses
Main finding
As reported in the abstract
ICU admission, assisted ventilation, renal insufficiency, mortality
- Neither metformin nor DPP4i prescription was associated with intensive care unit (ICU) admission, need for assisted ventilation, or mortality
- Insulin prescription was associated with increased ICU admission but not with need for assisted ventilation or mortality
- No association of any of these medications with development of renal insufficiency
Observational data: associations, not effects.
Original publication
Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019–Related Hospital Outcomes in Patients with Type 2 Diabetes. Endocr Pract. Published 9 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →